Zacks Investment Research reaffirmed their buy rating on shares of Vistagen Therapeutics (NASDAQ:VTGN) in a research note issued to investors on Saturday morning. The brokerage currently has a $1.00 target price on the stock.
According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “
Separately, Chardan Capital decreased their target price on Vistagen Therapeutics from $30.00 to $22.00 and set a buy rating for the company in a research report on Thursday, February 8th.
Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Monday, February 12th. The company reported ($0.24) earnings per share (EPS) for the quarter. equities analysts predict that Vistagen Therapeutics will post -1.89 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Sabby Management LLC acquired a new position in shares of Vistagen Therapeutics during the fourth quarter worth approximately $2,352,000. Sphera Funds Management LTD. lifted its holdings in shares of Vistagen Therapeutics by 17.8% during the fourth quarter. Sphera Funds Management LTD. now owns 1,247,251 shares of the company’s stock worth $1,384,000 after buying an additional 188,865 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Vistagen Therapeutics by 131.6% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 104,414 shares of the company’s stock worth $116,000 after buying an additional 59,338 shares during the last quarter. Institutional investors own 20.56% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Vistagen Therapeutics (VTGN) Rating Reiterated by Zacks Investment Research” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3340904/vistagen-therapeutics-vtgn-rating-reiterated-by-zacks-investment-research.html.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.